Triapine
- Generic Name
- Triapine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C7H9N5S
- CAS Number
- 143621-35-6
- Unique Ingredient Identifier
- U4XIL4091C
- Background
Triapine has been used in trials studying the treatment of Leukemia, Lung Cancer, Kidney Cancer, Prostate Cancer, and Pancreatic Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
- Conditions
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT00077545
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Cancer Therapeutics Research Group
- Target Recruit Count
- 31
- Registration Number
- NCT00077415
- Locations
- 🇸🇬
National University of Singapore, Singapore, Singapore
🇸🇬National Cancer Centre - Singapore, Singapore, Singapore
🇸🇬Cancer Institute at National University Hospital, Singapore, Singapore
A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00077350
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRelapsing Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00077181
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer
- First Posted Date
- 2004-01-12
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT00075504
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma
- Conditions
- First Posted Date
- 2004-01-12
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 19
- Registration Number
- NCT00075660
- Locations
- 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
- Conditions
- First Posted Date
- 2003-09-09
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Registration Number
- NCT00016874
- Locations
- 🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
🇺🇸New York Presbyterian Hospital - Cornell Campus, New York, New York, United States
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
- Conditions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Registration Number
- NCT00064090
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Vion Pharmaceuticals
- Registration Number
- NCT00064064
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
🇺🇸Sarah Cannon Cancer Center at Centennial Medical Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.